Cellectis - Rasio nilai perusahaan marang dodolan CLLS

Logo perusahaan publik Cellectis S.A. (CLLS)

Cellectis S.A. (CLLS) is facing a liquidity shortage due to costly development efforts. However, diversification through unique gene editing for various types of cancer mitigates these risks. In-house manufacturing facilities minimize outsourcing, which supports the business's enterprise value-to-revenue ratio. The 211.45 metric indicates the status of market valuations, capturing the current trend shown on this chart.

Cellectis SA (CLLS): Rasio nilai perusahaan marang pendapatan saka 23.11.2025 nganti 19.11.2026

Rincian metrik keuangan lan pasar Cellectis (CLLS)

Pambiji fundamental:Cellectis SA (CLLS)
Barang utama cellectis.com

This indicator determines investment reliability by comparing the total enterprise value to the volume of generated revenue. The metric eliminates the impact of leverage, revealing the gap between market expectations and actual cash flows. Analyzing the EV/Sales ratio allows investors to filter out speculative noise from genuine growth. For Cellectis S.A. (CLLS), such a valuation is critical, as the market capitalization relies on the value of TALEN patents. Exclusive contracts with pharmaceutical behemoths provide the fundamental basis for current quotes.